DiscoveryProbe™ FDA-approved Drug Library: Benchmarking High-Throughput Drug Repositioning

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) contains 2,320 bioactive compounds, each clinically approved by agencies such as FDA, EMA, HMA, CFDA, and PMDA. The library facilitates high-throughput and high-content screening for drug repositioning and pharmacological target discovery (Pladevall-Morera et al., 2022, DOI). Compounds are supplied as 10 mM DMSO solutions, stable for up to 24 months at -80°C, supporting reproducible results. The library encompasses a wide range of mechanisms, including enzyme inhibitors, receptor modulators, and signal pathway regulators. APExBIO offers multiple format options to accommodate diverse research workflows.

Biological Rationale

Drug repositioning leverages existing, clinically approved compounds to discover novel therapeutic applications, reducing cost and development time compared to de novo drug discovery (Pladevall-Morera et al., 2022). The DiscoveryProbe™ FDA-approved Drug Library capitalizes on this principle by providing a standardized set of compounds with known safety and pharmacokinetics. This approach is particularly useful in cancer and neurodegenerative disease research, where rapid identification of effective agents is critical (internal). Unlike preclinical libraries, all included compounds have been evaluated in humans, ensuring translational relevance. Mechanistic diversity—spanning receptor tyrosine kinase inhibitors, enzyme inhibitors, and ion channel modulators—enables comprehensive pathway interrogation and target validation. Standardized concentration (10 mM in DMSO) and stringent storage conditions (-20°C to -80°C) maintain compound integrity, minimizing experimental variability.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The library consists of agents with well-characterized, diverse mechanisms of action. Representative compound classes include:

• Receptor Modulators: Agonists and antagonists targeting GPCRs, receptor tyrosine kinases (RTKs), and nuclear receptors.
• Enzyme Inhibitors: Molecules inhibiting kinases (e.g., PDGFR inhibitors), topoisomerases (e.g., doxorubicin), and metabolic enzymes (e.g., metformin for AMPK).
• Ion Channel Modulators: Agents regulating calcium, potassium, and sodium channels.
• Signaling Pathway Regulators: Compounds modulating the PI3K/AKT/mTOR, MAPK, and Wnt pathways.

Each compound's mechanism is referenced by regulatory documentation or primary literature, ensuring traceability. For example, multi-targeted RTK inhibitors within the library have demonstrated efficacy in ATRX-deficient glioma models (Pladevall-Morera et al., 2022). The inclusion of drugs with established clinical indications, such as atorvastatin (HMG-CoA reductase inhibitor) and metformin (AMPK activator), broadens the library's utility for pathway-based phenotypic screens.

Evidence & Benchmarks

• ATRX-deficient high-grade glioma cells show increased susceptibility to specific RTK and PDGFR inhibitors present in the DiscoveryProbe™ FDA-approved Drug Library (Pladevall-Morera et al., 2022).
• All 2,320 compounds are supplied as pre-dissolved 10 mM DMSO solutions, validated for stability for 12 months at -20°C and 24 months at -80°C (APExBIO).
• The library enables high-throughput screening (HTS) and high-content screening (HCS) in both 96-well and deep-well plate formats, compatible with automated platforms (internal).
• Drug repositioning screens using this library have identified combinatorial regimens—such as RTKi plus temozolomide—that enhance cytotoxicity in glioma models (Pladevall-Morera et al., 2022).
• Each compound’s regulatory status is traceable to major authorities (FDA, EMA, HMA, CFDA, PMDA), facilitating translational research and clinical trial design (APExBIO).

This article extends the analysis of DiscoveryProbe FDA-approved Drug Library: Accelerating Dr... by providing peer-reviewed evidence for the efficacy of specific inhibitor classes against genetically defined cancer models, enabling more targeted screening strategies.

See also: DiscoveryProbe FDA-approved Drug Library: Transforming Hi... for additional workflow integration case studies; this article updates with current stability and regulatory traceability data.

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library supports applications in:

• Drug repositioning screening for oncology and neurodegeneration.
• Pharmacological target identification via phenotypic assays.
• Mechanistic pathway analysis using compounds with annotated MoAs.
• Combination therapy screening to find synergistic drug pairs.

However, certain boundaries must be recognized:

Common Pitfalls or Misconceptions

• Not all compounds are active in every cell type or disease context; mechanism-specific effects must be validated.
• The library does not include investigational or preclinical compounds—only those with established regulatory approval or pharmacopeia listing.
• Compound solubility in DMSO does not guarantee aqueous or biological solubility in assay conditions; optimization may be required.
• Stability claims apply to specified storage temperatures; deviations can compromise integrity.
• Annotated mechanisms are based on primary action; off-target effects are possible and require independent validation.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is compatible with standard HTS and HCS instrumentation. Compounds are distributed in 96-well microplates, deep well plates, or 2D barcoded screw-top storage tubes for automated liquid handling. Each well contains a 10 mM solution in DMSO, supporting dilution series for dose-response studies. Shipment is performed on blue ice (evaluation samples) or at ambient temperature for bulk orders, per researcher preference (APExBIO). To ensure data reproducibility, researchers should maintain storage at -20°C or -80°C and minimize freeze-thaw cycles. For assay integration, typical working concentrations range from 0.1 μM to 10 μM, depending on cell type and endpoint. Data management is facilitated by 2D barcoding and digital inventory tracking. For troubleshooting and advanced integration, refer to Selective Mechanistic Modulation and Strategic Opportunit..., which details best practices for library-based pharmacological screening; this article adds new evidence on RTK/PDGFR inhibitor efficacy and current storage guidelines.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library from APExBIO sets a benchmark for FDA-approved bioactive compound libraries in translational research. Its curated, mechanism-diverse collection enables rapid, reproducible drug repositioning, target identification, and mechanistic validation. Peer-reviewed studies have demonstrated its impact in oncology, particularly in identifying vulnerabilities in ATRX-deficient glioma models (Pladevall-Morera et al., 2022). Future directions include expanding mechanistic annotation, integrating with omics data, and leveraging AI-driven analytics for predictive screening. Consistent storage, format flexibility, and validated regulatory provenance ensure the library’s ongoing relevance for high-throughput and high-content screening workflows.